UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): ~~November~~February 5, ~~2007~~2008

Omrix Biopharmaceuticals, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)

Delaware	000-51905	52-2147005
_____________________ (State or other jurisdiction	_____________ (Commission	______________ (I.R.S. Employer
of incorporation)	File Number)	Identification No.)
630 Fifth Avenue, New York, New York		10111
One Rockefeller Center, Suite 2322, New York, New York		10020
_________________________________ (Address of principal executive offices)		___________ (Zip Code)


Registrant’s telephone number, including area code:		212-887-6500

Not Applicable
______________________________________________
Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Top of the Form

Item 2.02 Results of Operations and Financial Condition.

On ~~November~~February 5, ~~2007~~2008, Omrix Biopharmaceuticals, Inc. (the ~~registrant~~"Registrant") ~~announced~~issued ~~its~~a ~~results~~press ofrelease ~~operations~~regarding preliminary unaudited results for the fourth quarter and year ended ~~September~~December 3031, ~~2007.~~20007 and expected product sales guidance for 2008. A copy of the related press release is attached as Exhibit 99.1 to this Current Report on Form 8-K, which is being furnished, but not filed, pursuant to Item 2.02 of this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit 99.1 Press Release, dated February 5, 2008, announcing the Registrant’s preliminary unaudited results for the fourth quarter and year ended December 31, 2007.

Top of the Form

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Omrix Biopharmaceuticals, Inc.
November 5, 2007	By:	Ana Stancic
February 5, 2008	By:	Nanci Prado
		Name: Ana Stancic
		Name: Nanci Prado
		Title: Executive Vice President and Chief Financial Officer
		Title: Vice President and General Counsel

Top of the Form

Exhibit Index

Exhibit No.		Description
99.1		Press Release, dated ~~November~~February 5, ~~2007~~2008, announcing the ~~Company~~Registrant’s ~~results~~preliminary ofunaudited ~~operations~~results for the fourth quarter and year ended ~~September~~December 3031, 2007.

Filing Compare · Omrix Biopharmaceuticals, Inc.